Literature DB >> 29573085

Radiomics strategy for glioma grading using texture features from multiparametric MRI.

Qiang Tian1, Lin-Feng Yan1, Xi Zhang2, Xin Zhang1, Yu-Chuan Hu1, Yu Han1, Zhi-Cheng Liu1, Hai-Yan Nan1, Qian Sun1, Ying-Zhi Sun1, Yang Yang1, Ying Yu1, Jin Zhang1, Bo Hu1, Gang Xiao1, Ping Chen1, Shuai Tian3, Jie Xu3, Wen Wang1, Guang-Bin Cui1.   

Abstract

BACKGROUND: Accurate glioma grading plays an important role in the clinical management of patients and is also the basis of molecular stratification nowadays. PURPOSE/HYPOTHESIS: To verify the superiority of radiomics features extracted from multiparametric MRI to glioma grading and evaluate the grading potential of different MRI sequences or parametric maps. STUDY TYPE: Retrospective; radiomics. POPULATION: A total of 153 patients including 42, 33, and 78 patients with Grades II, III, and IV gliomas, respectively. FIELD STRENGTH/SEQUENCE: 3.0T MRI/T1 -weighted images before and after contrast-enhanced, T2 -weighted, multi-b-value diffusion-weighted and 3D arterial spin labeling images. ASSESSMENT: After multiparametric MRI preprocessing, high-throughput features were derived from patients' volumes of interests (VOIs). The support vector machine-based recursive feature elimination was adopted to find the optimal features for low-grade glioma (LGG) vs. high-grade glioma (HGG), and Grade III vs. IV glioma classification tasks. Then support vector machine (SVM) classifiers were established using the optimal features. The accuracy and area under the curve (AUC) was used to assess the grading efficiency. STATISTICAL TESTS: Student's t-test or a chi-square test were applied on different clinical characteristics to confirm whether intergroup significant differences exist.
RESULTS: Patients' ages between LGG and HGG groups were significantly different (P < 0.01). For each patient, 420 texture and 90 histogram parameters were derived from 10 VOIs of multiparametric MRI. SVM models were established using 30 and 28 optimal features for classifying LGGs from HGGs and grades III from IV, respectively. The accuracies/AUCs were 96.8%/0.987 for classifying LGGs from HGGs, and 98.1%/0.992 for classifying grades III from IV, which were more promising than using histogram parameters or using the single sequence MRI. DATA
CONCLUSION: Texture features were more effective for noninvasively grading gliomas than histogram parameters. The combined application of multiparametric MRI provided a higher grading efficiency. The proposed radiomic strategy could facilitate clinical decision-making for patients with varied glioma grades. LEVEL OF EVIDENCE: 3 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2018;48:1518-1528.
© 2018 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  SVM; glioma grading; multiparametric MRI; radiomics; texture feature

Mesh:

Year:  2018        PMID: 29573085     DOI: 10.1002/jmri.26010

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  58 in total

1.  CT radiomics may predict the grade of pancreatic neuroendocrine tumors: a multicenter study.

Authors:  Dongsheng Gu; Yabin Hu; Hui Ding; Jingwei Wei; Ke Chen; Hao Liu; Mengsu Zeng; Jie Tian
Journal:  Eur Radiol       Date:  2019-06-21       Impact factor: 5.315

2.  MRI radiomics analysis for predicting preoperative synchronous distant metastasis in patients with rectal cancer.

Authors:  Huanhuan Liu; Caiyuan Zhang; Lijun Wang; Ran Luo; Jinning Li; Hui Zheng; Qiufeng Yin; Zhongyang Zhang; Shaofeng Duan; Xin Li; Dengbin Wang
Journal:  Eur Radiol       Date:  2018-11-09       Impact factor: 5.315

3.  Non-invasive tumor decoding and phenotyping of cerebral gliomas utilizing multiparametric 18F-FET PET-MRI and MR Fingerprinting.

Authors:  Johannes Haubold; Aydin Demircioglu; Marcel Gratz; Martin Glas; Karsten Wrede; Ulrich Sure; Gerald Antoch; Kathy Keyvani; Mathias Nittka; Stephan Kannengiesser; Vikas Gulani; Mark Griswold; Ken Herrmann; Michael Forsting; Felix Nensa; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-06       Impact factor: 9.236

4.  Do the combination of multiparametric MRI-based radiomics and selected blood inflammatory markers predict the grade and proliferation in glioma patients?

Authors:  Jing Guo; Jialiang Ren; Junkang Shen; Rui Cheng; Yexin He
Journal:  Diagn Interv Radiol       Date:  2021-05       Impact factor: 2.630

Review 5.  Can artificial intelligence overtake human intelligence on the bumpy road towards glioma therapy?

Authors:  Precilla S Daisy; T S Anitha
Journal:  Med Oncol       Date:  2021-04-03       Impact factor: 3.064

Review 6.  Emerging MRI Techniques to Redefine Treatment Response in Patients With Glioblastoma.

Authors:  Fabrício Guimarães Gonçalves; Sanjeev Chawla; Suyash Mohan
Journal:  J Magn Reson Imaging       Date:  2020-03-19       Impact factor: 4.813

7.  Deep Convolutional Radiomic Features on Diffusion Tensor Images for Classification of Glioma Grades.

Authors:  Zhiwei Zhang; Jingjing Xiao; Shandong Wu; Fajin Lv; Junwei Gong; Lin Jiang; Renqiang Yu; Tianyou Luo
Journal:  J Digit Imaging       Date:  2020-08       Impact factor: 4.056

8.  Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.

Authors:  Minjae Kim; So Yeong Jung; Ji Eun Park; Yeongheun Jo; Seo Young Park; Soo Jung Nam; Jeong Hoon Kim; Ho Sung Kim
Journal:  Eur Radiol       Date:  2019-12-11       Impact factor: 5.315

9.  Predicting pathological subtypes and stages of thymic epithelial tumors using DWI: value of combining ADC and texture parameters.

Authors:  Bo Li; Yong-Kang Xin; Gang Xiao; Gang-Feng Li; Shi-Jun Duan; Yu Han; Xiu-Long Feng; Wei-Qiang Yan; Wei-Cheng Rong; Shu-Mei Wang; Yu-Chuan Hu; Guang-Bin Cui
Journal:  Eur Radiol       Date:  2019-03-15       Impact factor: 5.315

10.  Improved Glioma Grading Using Deep Convolutional Neural Networks.

Authors:  S Gutta; J Acharya; M S Shiroishi; D Hwang; K S Nayak
Journal:  AJNR Am J Neuroradiol       Date:  2020-12-10       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.